Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Last week the calendar produced nothing. On Friday it produced everything at once: two approvals, a cardiovascular label, and two full datasets at the biggest cardiology meeting of the year, each on the date its controller had set. Then the market sold all five. Roivant lost 7.6 percent on its first approval. Protagonist lost 3.5 percent on the day $275 million arrived. Cytokinetics lost 7.5 percent on a New England Journal paper whose every headline number had been public since May. Ionis and AstraZeneca gave more back on data they had summarized in July. Lilly, with a new label on the biggest drug in the industry, closed a dollar and a half lower.

The pattern is not that good news is bad. It is that in every case the delivered thing was narrower than the promised thing. Mounjaro's label says non inferior, not superior. Lisraya's first in class approval arrived inside a JAK class boxed warning. Mimrylo's endpoint is freedom from a needle, not from a clot. Aficamten's second event added safety detail to unchanged efficacy. Eplontersen's full data said the drug works only where nobody will use it. The empty date taught us to underwrite the controller, not the calendar. This week's through line is the next step: underwrite the label, not the headline. We will tally every catalyst delivered this week, starting with Monday's reported pricing deals, and count how many got paid. 👉 Read Full Analysis

🏛️ FDA

Two queue reviews delivered inside their windows, and both stocks fell. ROIV | PTGX | TAK

The FDA approved Lisraya (brepocitinib), Priovant's JAK1 and TYK2 inhibitor, on August 27 as the first oral and first targeted therapy for dermatomyositis in adults, and a day later approved Takeda's Mimrylo (rusfertide) as the first hepcidin mimetic for polycythemia vera. Both were priority reviews with third quarter target dates; both arrived with a month to spare. The Lisraya release reports that 55 percent of patients reached at least moderate improvement with minimal or no steroids versus 30 percent on placebo, and the label carries the JAK class boxed warning for infections, mortality, malignancy, cardiovascular events, and thrombosis. Mimrylo's VERIFY trial kept 76.9 percent of patients free of phlebotomy in weeks 20 to 32 against 32.9 percent on placebo, with injection site reactions in 56 percent. Neither company disclosed a price. Protagonist, which discovered rusfertide and opted out of US co commercialization in April, said the approval triggers $275 million on top of $849.5 million of cash at June 30. Roivant closed at $34.71, down 7.6 percent; Protagonist at $144.33, down 3.5 percent; Takeda unchanged at $18.03, per market data. Two rare disease approvals, two on time reviews, two lower closes.

💊 Obesity and Cardiometabolic

Mounjaro got its heart label, and the label says non inferior. LLY | NVO

The FDA approved Mounjaro (tirzepatide) on August 28 to lower the risk of cardiovascular death, non fatal heart attack, or non fatal stroke in adults with type 2 diabetes at high risk, the first dual GIP and GLP-1 agonist with a cardiovascular indication. The evidence is SURPASS-CVOT, 13,299 patients followed a median 210 weeks against Trulicity, a comparator with its own proven cardiovascular benefit. The hazard ratio was 0.92 with a 95.3 percent confidence interval of 0.83 to 1.01; Lilly's release states plainly that non inferiority was demonstrated and superiority was not. The headline reads as an 8 percent reduction. The label reads as parity with a drug that already had the claim. Both are true, and the distance between them is the commercial argument Novo will make, since Ozempic and Wegovy carry superiority based cardiovascular labels from placebo controlled trials. Lilly closed at $1,174.61, effectively flat. Separately, Fierce Pharma's tracker, citing IQVIA via Citi, put Foundayo at 40,862 weekly US scripts, its first week above 40,000, against roughly 175,000 for the Wegovy pill.

❤️ Cardiology

ESC was the second event we said to watch, and it repriced old numbers. IONS | AZN | ALNY | CYTK | BMY

On Friday we wrote that the congress presentation is now where magnitude gets priced. Munich proved it inside 48 hours. Eplontersen's CARDIO-TTRansform, 1,432 patients, produced a rate ratio of 0.89 (p=0.277) on cardiovascular death and recurrent events through 140 weeks, with no additional benefit in the 57 percent already on a stabilizer and a nominally significant benefit only as monotherapy, per the ESC presentation reported by HCPLive. The topline miss was public on July 9; the shape of the miss was not, and Ionis closed down 2.2 percent, AstraZeneca down 1.1 percent, while Alnylam fell as much as 5.5 percent intraday before closing flat. Cytokinetics presented ACACIA-HCM with a New England Journal paper: a 3.0 point KCCQ difference, a 0.67 mL/kg/min peak VO2 difference, and ejection fraction below 50 percent in 10.5 percent of patients versus 0.8 percent. Every one of those numbers was in the May 5 topline. The stock closed down 7.5 percent at $72.09 on four times normal volume. And milvexian's LIBREXIA ACS, 14,194 patients, printed a 1.05 hazard ratio nine months after BMS and J&J stopped it for futility. Direction was known in all three cases. The market paid for magnitude anyway.

🎗️ Oncology

The first personalized mRNA vaccine to fail on survival failed alone, in the coldest tumor. BNTX | MRNA | MRK

BioNTech and Genentech terminated the Phase 2 trial of autogene cevumeran as adjuvant monotherapy in ctDNA positive resected colorectal cancer after the data safety monitoring board identified a numerical imbalance in overall survival favoring control, per BioNTech's August 28 filing; Genentech told Fierce Biotech there were more deaths in the vaccine arm. The trial had crossed a futility boundary in October 2025 and was continued because the data were immature. The pancreatic program, which combines the vaccine with checkpoint inhibition and chemotherapy, continues. This is the first time a monitoring board has stopped an individualized mRNA vaccine on a survival signal, and it landed nine days after Merck and Moderna's INTerpath-001 met both endpoints in melanoma. The difference is the whole story: INTerpath is vaccine plus Keytruda in an immune responsive tumor; this was vaccine alone in microsatellite stable colorectal cancer, the setting the class was least likely to work in. It does not read across to the melanoma filing. It does close the monotherapy question. BioNTech closed at $102.08, down 8.4 percent; Moderna at $137.99, down 3.3 percent, per market data. Still no congress placement for INTerpath as of Sunday night.

🩺 Medtech

Boston Scientific's outage now reaches the factory floor. BSX

Boston Scientific's newsroom update, current as of Sunday, says the incident identified August 25 affects the ability to manufacture products as well as process and ship orders, extending the disclosed impact from the order desk into production. The company can take orders electronically but cannot process or ship them, new remote monitoring communicators cannot be activated, and it has found no impact on implanted device function or on patients already being monitored. The new detail is a target: partial restoration of shipping for some products this week, with confidence in recovery described as increasing and the full timeline still unknown. Materiality remains undetermined in the August 26 8-K. BSX closed at $46.84 Friday, essentially flat on the day and about 6 percent below its August 25 close, per market data. Manufacturing disruption is a different animal from a shipping backlog: backlogs ship when systems return, while lost production days do not come back. Watch whether the eventual quantification counts days of production or days of shipping.

💉 Vaccines

The XFG shots are approved, and the eligibility architecture is the same as last year's. PFE | MRNA | NVAX | SNY

The FDA approved the 2026 to 2027 COVID-19 vaccines on August 27: Pfizer and BioNTech's Comirnaty XFG, Moderna's Spikevax and mNexspike, and Novavax's Nuvaxovid, which Sanofi markets, all matched to the XFG subvariant of the JN.1 lineage. Eligibility follows the 2025 template: adults 65 and older, and younger people with at least one condition that raises the risk of severe disease, with minimum ages of six months for Spikevax, five years for Comirnaty, and twelve for the other two. Per Pharmacy Times, the agency treated the strain change as an adaptation requiring only nonclinical and manufacturing data. Pfizer said shipping began the same day. What is different this year is downstream: Medical Daily reports that the CDC's advisory committee has lacked a functioning quorum since a court ruling in March and has no meeting scheduled, so there is no federal recommendation attached to the new formula, and coverage for anyone outside the label groups depends on state pharmacy rules and individual plans. That is a single outlet's account and we attribute it as such. The manufacturing side performed on schedule; the recommendation side has no schedule.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

📋 The Week in Review

Five catalysts arrived on Friday and five stocks closed lower, which is the week's question in one line: what is a delivered catalyst worth once you read the label? We count through Friday. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →